Humanigen Inc. (HGEN) Announces NIH/NIAID Lock of ACTIV-5/BET-B Database, On Track for Results in July

Humanigen, Inc. (Nasdaq: HGEN) confirms that notice was received today from the National Institute of Allergy and Infectious Diseases (NIAID) that they have completed database lock for the Big Effect Trial of lenzilumab (BET-B) being conducted as part of the National Institutes of Health (NIH) public-private partnership Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV). NIH/NIAID has cleaned and locked the blinded data in the study. This significant milestone allows NIH/NIAID to complete topline analysis. Humanigen expects to receive topline results from NIH/NIAID in July.

“Locking the database marks a crucial step in the process of NIH/NIAID completing the evaluation of lenzilumab for patients hospitalized with COVID-19 and reporting the results of its study. We look forward to being able to share topline results once received from NIH/NIAID,” said Cameron Durrant, Chairman and Chief Executive Officer, Humanigen.

Lenzilumab is an investigational product and is not approved or authorized in any country.

You May Also Be Interested In

• Inhibikase Therapeutics (IKT) Issues Letter to Shareholders and Provides Update on Development Programs
• Smart for Life (SMFL) Appoints Heather Granato to its Board
• Neurosense Therapeutics (NRSN) Reports Positive Data Validating Phase 2b Topline Readout